Locally advanced female urethral adenocarcinoma of enteric origin: The role of adjuvant chemoradiation and brief review  by Chen, Ling-Ping et al.
Kaohsiung Journal of Medical Sciences (2011) 27, 150e154ava i lab le at www.sc iencedi rect .com
journal homepage: h t tp : / /www.k jms-on l ine .comCASE REPORT
Locally advanced female urethral adenocarcinoma
of enteric origin: The role of adjuvant chemoradiation
and brief review
胚胎起源自腸道之局部性晚期女性尿道腺癌：輔助性化學及放射線治
療的角色及文獻回顧Ling-Ping Chen a,c, Shyh-Jer Lin a,c, Ting-Ying Fu b,c, Ming-Sun Yu a,c,*
陳苓萍 a,c, 林世哲 a,c, 傅婷瑛 b,c, 余明生 a,c,*aDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
bDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
cNational Yang-Ming University, School of Medicine, Taipei, Taiwan
Received 18 January 2010; accepted 2 September 2010
Available online 16 February 2011KEYWORDS
Adjuvant
chemotherapy;
Chemoradiation;
Irinotecan;
Urethral
adenocarcinoma;
Urethral carcinoma
關鍵詞
輔助性化學治療;
化學及放射線治療;
喜樹鹼;
尿道腺癌;
尿道腫瘤* Corresponding author. Division of
386, Ta-Chung lst Road, Kaohsiung 813
E-mail address: xguaalu@yahoo.co
1607-551X/$36 Copyright ª 2011, Else
doi:10.1016/j.kjms.2010.12.009Abstract Primary female urethral adenocarcinoma (FUA) is rare and has a poor prognosis.
The common manifestations include urethrorrhagia, urinary frequency, dysuria, urethral
obstructions, focal tenderness, and urinary tract infection. These symptoms are neither diag-
nostic nor pathognomonic; therefore, a delay in diagnosis and even a misdiagnosis is hardly
uncommon. The histogenesis of FUAs may have derived from urethritis glandularis, Mullerian
ducts, Skene’s glands, or mixed origins. Tumors of different embryologic origins displayed
heterogeneous pathological morphology and immunohistochemistical phenotypes. Because
of its rarity and the lack of large-scale studies, there is no current consensus on the optimal
treatment of urethral adenocarcinomas. Here, we report two cases of locally advanced FUA
of enteric origin. They manifested as slightest warning symptoms of urinary tract infection
and stress urinary incontinence, respectively. One patient died of disease progression 2 months
after curative operation. The other patient underwent surgery followed by adjuvant irinote-
can-containing chemoradiation, and the effect was at least modest. Hence, we recommend
adjuvant chemoradiation in locally advanced FUA. Individualizing cancer care of chemoregi-
mens in accordance with the tumor origins may probably be beneficial in FUAs.Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital,
, Taiwan.
m.tw (M.-S. Yu).
vier Taiwan LLC. All rights reserved.
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immunostains. (DeF) In Case 2, the
neoplastic cells in a glandular patt
hematoxylin and eosin in A and D; C摘要 原發性女性尿道腺癌為一罕見且預後不佳的惡性腫瘤。常見臨床表徵包含出血、頻尿、尿
道阻塞症狀、局部疼痛或泌尿道感染。臨床因無特異表現，延誤診斷或誤診並非罕見。過去文獻
證實原發性女性尿道腺癌病理型態具多樣性，因腫瘤起源自不同組織，而有不同細胞型態及免疫
組織化學染色特徵。此外，原發性女性尿道腺癌屬罕見疾病且缺乏大型臨床試驗，目前對最佳治
療方式缺乏共識。在此報告兩例女性尿道腺癌個案，病患均屬於局部性晚期病灶且起源自腸道，
兩人分別以泌尿道感染及應力性失禁為初始表現。其中一人接受治癒性手術後2個月死於疾病進
展，另一個病人則於術後接受輔助性放射線治療及含有喜樹鹼（irinotecan）的輔助性化學治
療，其成效不俗。因而針對局部性晚期原發性女性尿道腺癌，建議病患術後接受輔助性化學及放
射線治療，同時，依據腫瘤胚胎起源選擇個別不同的化療處方或許是未來可考量的方向。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Primary female urethral adenocarcinoma (FUA) is rare. Ten
percent to 16% of female urethral carcinomas are adeno-
carcinomas, and they comprise less than 0.003% of all
female urogenital tract malignancies [1,2]. The common
symptoms of FUA consist of urethrorrhagia, urinary
frequency, dysuria, urethral obstruction, focal tenderness,
and urinary tract infection [3]. However, neither of these
symptoms are diagnostic nor pathognomonic; hence,
delayed diagnosis or misdiagnosis is not uncommon.
During October 1980 to December 2009, there were 35
patients with pathologically proven urethral adenocarci-
noma in our hospital. Only two patients had true primary
FUA. Because of its rarity and the lack of large-scale
studies, there is no current consensus on the optimal
treatment. We retrospectively compared the clinical
manifestations, pathological characteristics, treatment
modalities, and outcomes in these two patients with locally
advanced disease. To our knowledge, adjuvant irinotecan-
containing regimen in urethral adenocarcinoma was never
reported before.umor was moderately to poorl
neoplasm was moderately diffe
ern. Immunohistochemically, th
K7 in B and E; CK20 in C and FCase presentation
Case 1
A 69-year-old woman presented with urinary frequency for
1month. She was treated as urinary tract infection in a local
hospital and her symptoms subsided for a short period. In
September 2002, she visited our hospital after symptoms
relapsed, and a noticeable mass was found in the anterior
vaginal wall during Foley catheterization. A gynecologist
was consulted, but no gynecological abnormality was noted
in ultrasonography. The abdominal computed tomography
(CT) showed urethral diverticulum with stone, and
magnetic resonance imaging (MRI) revealed a suspicious
periurethral tumor with irregular border and intratumoral
hemorrhage. Chest X-ray and whole body bone scan were
negative. So she received radical cystectomy with ileal
conduit diversion. The pathology revealed moderately to
poorly differentiated adenocarcinoma arising from the
urethral diverticulum (Fig. 1A). Tumor cells invaded the
submucosa of the vaginal wall with vascular involvement
(pT3N0M0). Immunohistochemically, the tumor cells werey differentiated adenocarcinoma with positive CK7 and CK20
rentiated adenocarcinoma, which was composed of clusters of
ese tumor cells were positive for CK7 and CK20 stains (400;
). CKZ cytokeratin.
152 L.-P. Chen et al.positive for cytokeratin 7 (CK7) and cytokeratin 20 (CK20)
and negative for prostatic-specific antigen (PSA) immunos-
tains (Fig. 1B and C). The patient asked to postpone adju-
vant chemoradiation because of persistent epigastragia.
Panendoscopy disclosed esophageal and gastric ulcer only.
However, she complained about shortness of breath 2
months after operation, and chest X-ray revealed multiple
metastases in the lung. Chest CT reconfirmed the metas-
tases. Her family requested do-not-resuscitate and she died
of respiratory failure soon.
Case 2
For stress urinary incontinence, a 49-year-old woman
received bladder neck suspension with tension-free vaginal
tape in a local hospital. Since the completion of the above
procedure, she began to complain about urinary frequency
and dysuria, and the symptoms were considered to be asso-
ciated with oversuspension. She received two further oper-
ations aiming to release the tension. However, her symptoms
persisted and she attended our clinic 6months after tension-
free vaginal tape in April 2008. Cystometrogram and cystos-
copy were aborted because of urethral stricture. One
urethral-vaginal fistula was noted when she underwent ure-
throplasty, and pathology of the biopsy turned out to be
adenocarcinoma. The abdominal CT revealed a hypodense
nodule at the urethra with posteriolateral extension to the
vagina. The pelvic MRI showed a urethral tumor, 3.5 cm in
size, with anterior vaginal wall invasion. No other tumor was
demonstrated. All of her serum tumor markers were within
normal range, including PSA. Bone scintigraphy had no
evidence of bony involvement. She received urethrectomy,
anterior exenteration, ileal conduit, and pelvic lymph nodes
dissection. Pathology demonstrated moderately differenti-
ated adenocarcinoma (Fig. 1D) with invasion of the periure-
thral, vagina, paravaginal, paracervix, and prerectal soft
tissue (pT4N0M0). Surgical margins could not be properly
evaluated. Immunohistochemically, these tumor cells were
positive for CK7 and CK20 immunostains and negative for PSA
staining (Fig. 1E and F). For this unclear margin-free
advanced stage and no consensus on the treatment, we
commenced her on adjuvant radiotherapy followed by six
cycles of chemotherapy with Douillard regimen containing
irinotecan, fluorouracil, and leucovorin, one of the best-
known combinations in colorectal cancer. After finishing two
cycles of chemotherapy, she was intolerant to asthenia. NoTable 1 Histogenesis and pathological phenotypes of morpholo
Histogenesis Embryologic origin
Urethritis glandularis Intestinal metaplasia
Mullerian ductb Ovarian or fallopian tube
Paraurethral duct
Proximal part Cystic glandular metaplasia
Distal part Skene’s gland
a mAbDas1 is a monoclonal antibody reactive in areas of intestinal
b Mullerian duct or paramesonephric duct.
c Neuroendocrine differentiation correlates with mucin production.
CEAZ carcinoembryonic antigen; CKZ cytokeratin; PAPZ prostaticevidence of tumor recurrence was found in the following CT
and during gynecologist consultation, thus she asked to dis-
continue the chemotherapy. Six months after the operation,
she suffered from painful induration in the suprapubic area.
Pathology confirmed the presence of metastases after inci-
sional biopsy followed by wide excision. She was reluctant to
undergo salvage chemotherapy and received radiotherapy
only. Another 7 months later, her abdominal CT, MRI, and
bone scan documented a tumor relapse in the pubic
symphysis, but she refused palliative chemotherapy. She
suffered from fever and low abdominal pain a month later.
Abdominal CT disclosed bowel obstruction related to adhe-
sion band. Another cystic lesion with gas trapping and soft
tissue swelling was noted at the midline rectus muscle, and
abscess formation was likely. The abscess was spontaneously
drained from the previous incision line, followed by wound
dressing, debridement, and final suture. Nevertheless, stool-
like materials leaked from the suture and her symptoms
subsided after the fistula formation. She was under hospice
care since then.
Discussion
Urinary tract infection and stress urinary incontinence are
two of the most common conditions among women who
seek medical help [4,5]. Less than 10% of female urethral
cancer patients initially present with urinary incontinence
and only 5% with urinary tract infection [3,6]. Because
these symptoms are nonspecific, we should take into
account the possibility of urethral carcinomas in general
practice to make an early diagnosis and to prevent unnec-
essary interventions and severe complications (obstruction,
stricture, and fistula formation).
In addition, FUA may arise from urethritis glandularis,
Mullerian ducts (paramesonephric ducts), Skene’s glands
(paraurethral glands), or mixed origins. The major histo-
logical subtype is columnar/mucinous adenocarcinoma and
most columnar/mucinous lesions originate from urethritis
glandularis that transformed from intestinal metaplasia.
The microscopic appearance resembles colonic or endo-
metrial adenocarcinoma and is immunohistochemically
positive for CK7, CK20, and mAbDAS1 stains [7,8]. The
morphological pattern of either the signet ring cell or the
columnar/mucinous form depends on the degree of
neuroendocrine differentiation and mucin production.
Some FUA with proximal paraurethral duct origin comegy and immunohistochemistry
Typical morphology Positive immunostains
Columnar/mucinous CK7, CK20, mAbDas1a
Clear cell CA125
Signet ring cellc CEA
Cribriform PSA, PAP
metaplasia.
acid phosphatase; PSAZ prostatic-specific antigen.
Table 2 Adjuvant chemoradiation in locally advanced female urethral adenocarcinomas
Author Stage Adjuvant tx Chemotherapy regimens DFS Results
Awakura et al. [12] T3N0M0 C/T,a R/T Cisplatin, 5-fluorouracil NED NED for 2 yr
Davis et al. [13] T4N0M0 CCRT,b C/T Carboplatin, paclitaxel NED DOC
Dimarco et al. [14] T4N1M0 R/T, C/T Cisplatin-based 3 mo DOD at 5 mo
Dimarco et al. [14] T4N0M0 CCRT Cisplatin-based 13 mo DOC at 23 mo
Tanaka et al. [15] T4N0M0 CCRT Cisplatin, TS-1 5 mo DOD at 14 mo
Koizumi et al. [16] TxN1M0 R/T, C/T Cisplatin, 5-fluorouracil 6 mo DOD at 20 mo
Case 2 T4N0M0 R/T, C/T 5-Fluorouracil, irinotecan 6 mo Survival> 2 yr
a Intra-arterial chemotherapy followed by intravenous chemotherapy.
b Neoadjuvant CCRT.
CCRTZ concurrent chemoradiation; C/TZ chemotherapy; DFSZ disease-free survival; DOCZ death from other causes; DODZ death
from disease; moZmonths; NEDZ no evidence of disease; R/TZ radiation; txZ treatment.
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antigen staining [9]. Behind columnar/mucinous type
adenocarcinoma, there are around 15% of clear cell
adenocarcinomas in FUA [10]. The hypothesis of clear cell
adenocarcinomas arising from the Mullerian duct (origin of
ovary and fallopian tube) is supported by positive carbo-
hydrate antigen 125 immunostains [1]. Finally, the minor
subtype is cribriform adenocarcinoma. Tumors with distal
paraurethral duct origin come from female Skene’s glands
(homogeneity of male prostate gland) driving from the
same cribriform morphology are matched by positive
immunostains of PSA and prostatic acid phosphatase [11].
Meanwhile, elevated serum PSA that declines rapidly after
operation provides further evidence (Table 1).
Given the rarity and lack of large-scale studies, the
recommendations in the treatment of FUA are based on
general principles and extrapolations from other diseases.
Treatment choices for tumor of less than 2 cm include
irradiation or curative surgery with/without adjuvant
radiation. For bulky lesions, brachytherapy or external
beam radiotherapy significantly improves the local control
rate and preserves organ functions [6]. For locally advanced
disease, multimodality therapy is the current trend
[12e17]. Preoperative or postoperative irradiation is rec-
ommended, but the role of chemotherapy in reduction of
local recurrence or distant metastasis is not well docu-
mented. The platinum-based chemotherapy is usually given
based on the pooling data of metastatic nontransitional cell
carcinomas of the urothelial tract [18]. However, the limi-
tation in applying the result was the small percentage of
FUA patients in the retrospective study. Rather, embryo-
logic origin was never correlated with the treatment
modalities and outcomes. Another study reported that the
prognosis of advanced urethral carcinoma has been
improved by chemoradiation chiefly with 5-fluorouracil and
mitomycin-C [17]. The case series of locally advanced FUA
undergoing adjuvant chemoradiation found in the literature
were summarized in Table 2. According to the limited data,
either local or distant recurrence mostly occurred within
the first 6 months even after aggressive adjuvant therapy
(median duration, 5.5 months; range, 3e13 months).
Patients receiving adjuvant concurrent chemoradiation had
similar outcome with those taking alternative treatment
(Table 2). In addition to histology, the tumor size is the only
independent prognostic factor of female urethral cancer in
a multivariate analysis [6].In our patients, the microscopic morphology of tumors
was both columnar glandular patterns with strong positive
for CK7, CK20 and negative for PSA immunostains. Therefore,
the diagnosis of locally advanced FUA of enteric origin was
preferred. In Case 1, the patient died of rapid disease
progress 2 months after curative operation. In Case 2, the
patient received adjuvant radiation followed by Douillard
regimen, which was a well-documented first-line chemo-
therapy in metastatic colorectal cancer [19]. Despite the
incomplete courses of chemotherapy, this patient had
a disease-free survival period of 6 months and the effect was
at least modest compared with the median disease-free
duration, 5.5 months, in the previous review. However, it
was inconclusive whether radiation or chemotherapy or both
approaches contributed to the outcome. Furthermore, the
treatment for our patient was discontinued because of
intolerance of the side effect, and therefore we were unable
to predict the superior outcome after full courses of
chemotherapy. However, the indirect evidence supporting
the use of Douillard regimen in FUA comes from urachal
carcinomas (enteric type adenocarcinomas of urinary
bladder). The efficacy of 5-fluorouracil-based chemotherapy
is supported in the currently accruing clinical trials [20].
We conclude that adjuvant chemoradiation plays a role
in locally advanced FUA. In addition, irinotecan-containing
regimen proved at least modest efficacy in advanced FUAs
of enteric origin. Moreover, individualizing cancer care of
chemoregimens in accordance with the tumor embryologic
origins seems reasonable. However, the feasibility should
be further confirmed by larger prospective trials.References
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